Xirestomig (ATG-101) is a tetravalent 2+2'' PD-L1*4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs)[1].
Molekulargewicht:
(196.508 kDa)
Reinheit:
98.44
CAS Nummer:
[2756879-35-1]
Target-Kategorie:
PD-1/PD-L1,TNF Receptor
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
